Correlation of HBV genotypes to the therapeutic effect of PEG-interferon and the pathological changes of the liver of chronic hepatitis B patients.
- Author:
Jian-kun SHEN
1
;
Jin-lin HOU
;
Xin-nan PANG
;
Hong YANG
;
Zheng-ju XU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antiviral Agents; therapeutic use; DNA, Viral; blood; Female; Genotype; Hepatitis B e Antigens; blood; Hepatitis B virus; genetics; immunology; Hepatitis B, Chronic; blood; drug therapy; virology; Humans; Interferon-alpha; therapeutic use; Liver; drug effects; pathology; virology; Male; Middle Aged; Polyethylene Glycols; therapeutic use; Recombinant Proteins; Young Adult
- From: Journal of Southern Medical University 2008;28(7):1217-1218
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the correlation of HBV genotypes to the response to PEG-interferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients.
METHODSReal-time fluorescent PCR was used for HBV genotyping in 48 CHB patients, and the therapeutic effects of PEG-IFN and hepatic pathological changes were observed.
RESULTSNo obvious differences were noted in ALT and HBV DNA levels or negative rate for HBeAg between patients with genotypes B and C (P>0.05). The sustained response rate was significantly higher in genotype B than in genotype C patients 48 weeks o after the therapy.
CONCLUSIONHBV genotype is the main factor for predicting PEG-IFN therapy response in CHB patients, and the sustained response rate is significantly higher in genotype B than in genotype C patients.
